Axovant Sciences Ltd (NASDAQ:AXON)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $1.78 and last traded at $1.77, with a volume of 735749 shares trading hands. The stock had previously closed at $1.94.
AXON has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Axovant Sciences in a research note on Thursday, October 19th. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Wednesday, January 31st. BidaskClub upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 12th. Finally, Piper Jaffray Companies reiterated a “hold” rating on shares of Axovant Sciences in a research note on Friday, November 10th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.61.
The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. The company has a market capitalization of $208.96, a PE ratio of -0.83 and a beta of -0.97.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.